Renal Cell Carcinoma
Feature
Chatbots Seem More Empathetic Than Docs in Cancer Discussions
AI gives readable, high quality, and empathetic responses to social media queries about cancer.
Conference Coverage
Survey Spotlights Identification of Dermatologic Adverse Events From Cancer Therapies
Survey respondents classify and grade morbilliform, psoriasiform, and papulopustular rashes based on a review of photographs and text descriptions...
Conference Coverage
New mRNA Vaccines in Development for Cancer and Infections
Different forms and designations of mRNA vaccines are used, depending on the application and desired effect.
From the Journals
Can a Risk Score Predict Kidney Injury After Cisplatin?
Researchers have developed a risk algorithm to predict acute kidney injury after cisplatin administration and tested it using data from six US...
From the Journals
Do Patients Benefit from Cancer Trial Participation?
Researchers conduct a meta-analysis comprising 141 comparisons of an investigational drug and a control treatment, which include immunotherapies...
Feature
Do Health-Related Social Needs Raise Mortality Risk in Cancer Survivors?
Researchers examine links between mortality risk and health-related social needs in patients who had cancer.
From the Journals
Terminal Cancer: What Matters to Patients and Caregivers
Patients and caregivers are less aligned on decisions about cost containment than end-of-life goals.
Feature
The Long, Controversial Search for a ‘Cancer Microbiome’
Research raised as many questions as answers about what we do and don’t know about microbiota and cancer.
From the Journals
Few Cancer Survivors Meet ACS Nutrition, Exercise Guidelines
Researchers estimate more than 9,000 survivors’ adherence to weight, physical activity, fruit and vegetable consumption, and alcohol intake...
Conference Coverage
How Can Kidney Cancer Patients Benefit From New Combination Therapy?
Immunotherapy has expanded treatment options as an adjuvant and a first-line therapy in patients with renal cell carcinoma.
From the Journals
Most Targeted Cancer Drugs Lack Substantial Clinical Benefit
Researchers assess validity of the molecular targets and clinical benefits of genome-targeted cancer drugs approved in the United States from 2015...